-
Forward Look
A Diabetes Drug for Cancer?Lab results spur researchers to test low-cost medication on humans.
by Stephen Ornes
-
Forward Look
Cancer Screening: A Dose of RealityQ&A with H. Gilbert Welch, professor of medicine at the Dartmouth Institute for Health Policy and Clinical Practice.
by Sue Rochman
-
Forward Look
When Is “Cancer” Not Cancer?Does the word “cancer” discourage patients with very early disease from fully considering all their options?
by Stephen Ornes
-
Forward Look
The Avastin Roller CoasterUps and downs keep coming for Avastin as studies report on its effects for different cancers.
by Sue Rochman
-
Clinical Trials Game-Changer?
A new type of clinical trial aims to identify which drug is the best fit for each patient's tumor. Can this innovative model expedite new drug approvals?
by Sue Rochman
-
Cancer In America
Standard of CareResearch suggests that black patients, as a whole, aren't receiving the same level of treatment as white patients. Can building better bonds between doctors and patients help?
by Charlotte Huff
-
The HPV Cancer Connection: Take 2
New insights about HPV's role in multiple cancers are rapidly expanding, as are thoughts about who should be vaccinated against the virus, and why.
by Alanna Kennedy-Gorman
-
Healthy Habits
Just Another Meatless MondayMake room for tasty vegetarian dishes in your weekly menu.
by Alanna Kennedy-Gorman
-
Staying the Course
Patients are increasingly skipping treatment breaks and opting for ongoing treatment known as maintenance therapy to try to keep some types of cancer at bay.
by Melissa Weber
-
The Birth of a Targeted Therapy
A serendiptious discovery more than 50 years ago heralded a new age of cancer treatment.
by Jocelyn Selim
Cancer Talk
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer
Findings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff
Cancer Today Editors’ Picks: 2024Our favorite Cancer Today stories from 2024, as picked by the editors.